2,6-Dihydroxy-4-Methoxytoluene

2,6-Dihydroxy-4-Methoxytoluene

SCHEMBL1607351

COc1cc(O)c(C)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 1.00
ALDH1A1 P00352 2/20 0.53
ACHE P22303 1/20 0.52
HPGD P15428 3/20 0.50
ABL1 P00519 2/20 0.48
ABCB1 P08183 2/20 0.48
BCR P11274 2/20 0.48
MAPK1 P28482 2/20 0.47
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ERN1 O75460 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
PTPN1 P18031 2/20 0.46
KDM4E B2RXH2 2/20 0.46
MAPT P10636 2/20 0.46
GLA P06280 1/20 0.46
ELANE P08246 1/20 0.46
ALOX15 P16050 1/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12586702 0.87 CYP3A4 (0.77) CYP3A4ALDH1A1ACHEHPGDABL1
SCHEMBL30277943 0.85 CYP3A4 (0.74) CYP3A4ALDH1A1HPGDABL1ABCB1
SCHEMBL3300408 0.85 CYP3A4 (0.74) CYP3A4ALDH1A1HPGDABL1ABCB1
SCHEMBL14553798 0.84 CYP3A4 (0.71) CYP3A4ALDH1A1HPGDABL1ABCB1
SCHEMBL67338 0.80 CYP3A4 (0.67) CYP3A4ALDH1A1HPGDABL1ABCB1
SCHEMBL10521152 0.80 CYP3A4 (0.67) CYP3A4ALDH1A1ACHESMN1; SMN2TDP1
SCHEMBL12311286 0.79 CYP3A4 (0.63) CYP3A4ALDH1A1HPGDABL1ABCB1
SCHEMBL4646583 0.78 TDP1 (0.75) CYP3A4ALDH1A1HPGDABL1ABCB1
SCHEMBL10106588 0.77 CYP3A4 (0.62) CYP3A4ALDH1A1HPGDABL1ABCB1
SCHEMBL8867887 0.77 GAA (0.62) CYP3A4ALDH1A1ACHEHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0021716-B1 CONDENSATION PRODUCT AND LITHOGRAPHIC PRINTING PLATES CONTAINING SAID PRODUCT KONICA CORPORATION (JP) 1984-02-15 EP claimed
US-20180042899-A1 Method of Treating Transplant Rejection and Autoimmune Diseases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-02-15 US disclosed
EP-2438078-B1 NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES UNIV KANSAS (US) 2017-10-25 EP disclosed
US-9120774-B2 Novobiocin analogues having modified sugar moieties UNIVERSITY OF KANSAS (US) 2015-09-01 US disclosed
US-9120774-B2 Novobiocin analogues having modified sugar moieties UNIVERSITY OF KANSAS (US) 2015-09-01 US disclosed
US-9120774-B2 Novobiocin analogues having modified sugar moieties UNIVERSITY OF KANSAS (US) 2015-09-01 US disclosed
US-20140050694-A1 Method of Treating Transplant Rejection and Autoimmune Diseases WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-02-20 US disclosed
EP-1981889-B1 CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE SANOFI SA (FR) 2014-01-15 EP disclosed
US-8313734-B2 Malodour counteracting composition FIRMENICH SA (CH) 2012-11-20 US disclosed
US-20120252745-A1 NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-10-04 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed
US-4770973-A READABLE BY OPTICAL DEVICES AND FIXED BY LIGHT Kanzaki Paper Manufacturing Limited (JP) 1988-09-13 US disclosed
US-4575479-A HIGH SPEED; PHOTO-FIXING ABILITY RICOH COMPANY, LTD. (JP) 1986-03-11 US disclosed
US-4542394-A MULTILAYER-DIAZONIUM LAYER AND COUPLER LAYER CONTAINING BENZIMIDAZOLE COMPOUND RICOH COMPANY, LTD. (JP) 1985-09-17 US disclosed
EP-0065720-B1 PROCESS FOR PREPARING HYDROXYPHENYL AMINE DERIVATIVES CASSELLA Aktiengesellschaft (DE) 1985-01-09 EP disclosed
US-4477553-A AN O QUINONEDIAZIDE AND A DIHYDROXYBENZENE-BASED PHENOLIC OR POLYPHENYL RESIN BINDER; LITHOGRAPHIC PRINTING PLATES KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1984-10-16 US disclosed
US-4454521-A PETROLEUM RESIN LAYER RICOH COMPANY, LTD. (JP) 1984-06-12 US disclosed
EP-0021716-B1 CONDENSATION PRODUCT AND LITHOGRAPHIC PRINTING PLATES CONTAINING SAID PRODUCT KONICA CORPORATION (JP) 1984-02-15 EP disclosed
EP-0065720-A1 Process for preparing hydroxyphenyl amine derivatives CASSELLA Aktiengesellschaft (DE) 1982-12-01 EP disclosed
EP-0054258-A2 Photosensitive compositions KONICA CORPORATION (JP) 1982-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252745-A1 NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES HSP90AB1, HSP90AB2P, HSP90B1 CYP3A4 3151/4885ALDH1A1 3066/4885ACHE 4861/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA CYP3A4 2041/4885ALDH1A1 140/4885ACHE 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.